Cargando…
Review of clinical studies of perampanel in adolescent patients
AIM: To assess the clinical trial and real‐world data for adjunctive perampanel in adolescents and develop consensus recommendations to guide the use of perampanel in this population in clinical practice. METHODS: In May 2015, 15 epilepsy experts attended a Consensus Development Meeting to assess th...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036429/ https://www.ncbi.nlm.nih.gov/pubmed/27688936 http://dx.doi.org/10.1002/brb3.505 |
_version_ | 1782455553616773120 |
---|---|
author | Kim, Heung Dong Chi, Ching‐Shiang Desudchit, Tayard Nikanorova, Marina Visudtibhan, Anannit Nabangchang, Charcrin Chan, Derrick W. S. Fong, Choong Yi Chang, Kai‐Ping Kwan, Shang‐Yeong Reyes, Fe De Los Huang, Chao‐Ching Likasitwattanakul, Surachai Lee, Wang‐Tso Yung, Ada Dash, Amitabh |
author_facet | Kim, Heung Dong Chi, Ching‐Shiang Desudchit, Tayard Nikanorova, Marina Visudtibhan, Anannit Nabangchang, Charcrin Chan, Derrick W. S. Fong, Choong Yi Chang, Kai‐Ping Kwan, Shang‐Yeong Reyes, Fe De Los Huang, Chao‐Ching Likasitwattanakul, Surachai Lee, Wang‐Tso Yung, Ada Dash, Amitabh |
author_sort | Kim, Heung Dong |
collection | PubMed |
description | AIM: To assess the clinical trial and real‐world data for adjunctive perampanel in adolescents and develop consensus recommendations to guide the use of perampanel in this population in clinical practice. METHODS: In May 2015, 15 epilepsy experts attended a Consensus Development Meeting to assess the clinical trial data for perampanel, specific to the adolescent age group (12‐17 years) and develop consensus treatment recommendations. RESULTS AND DISCUSSION: Analysis of the adolescent subgroup data of three pivotal placebo‐controlled, double‐blind, phase 3 trials investigating perampanel in patients with ongoing focal epileptic seizures despite receiving one to three antiepileptic drugs found that perampanel 4–12 mg was superior to placebo. The tolerability profile of perampanel was generally acceptable. Adolescent patients receiving long‐term treatment with perampanel in an open‐label extension study maintained improvements in seizure control compared with baseline, with a favorable risk‐benefit profile. A phase 2 study showed that perampanel had no clinically important effects on cognitive function, growth, and development. CONCLUSION: Perampanel is a welcome addition to the armamentarium of existing antiepileptic drugs as it represents a new approach in the management of epilepsy, with a novel mechanism of action, and the potential to have a considerable impact on the treatment of adolescents with epilepsy. |
format | Online Article Text |
id | pubmed-5036429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-50364292016-09-29 Review of clinical studies of perampanel in adolescent patients Kim, Heung Dong Chi, Ching‐Shiang Desudchit, Tayard Nikanorova, Marina Visudtibhan, Anannit Nabangchang, Charcrin Chan, Derrick W. S. Fong, Choong Yi Chang, Kai‐Ping Kwan, Shang‐Yeong Reyes, Fe De Los Huang, Chao‐Ching Likasitwattanakul, Surachai Lee, Wang‐Tso Yung, Ada Dash, Amitabh Brain Behav Reviews AIM: To assess the clinical trial and real‐world data for adjunctive perampanel in adolescents and develop consensus recommendations to guide the use of perampanel in this population in clinical practice. METHODS: In May 2015, 15 epilepsy experts attended a Consensus Development Meeting to assess the clinical trial data for perampanel, specific to the adolescent age group (12‐17 years) and develop consensus treatment recommendations. RESULTS AND DISCUSSION: Analysis of the adolescent subgroup data of three pivotal placebo‐controlled, double‐blind, phase 3 trials investigating perampanel in patients with ongoing focal epileptic seizures despite receiving one to three antiepileptic drugs found that perampanel 4–12 mg was superior to placebo. The tolerability profile of perampanel was generally acceptable. Adolescent patients receiving long‐term treatment with perampanel in an open‐label extension study maintained improvements in seizure control compared with baseline, with a favorable risk‐benefit profile. A phase 2 study showed that perampanel had no clinically important effects on cognitive function, growth, and development. CONCLUSION: Perampanel is a welcome addition to the armamentarium of existing antiepileptic drugs as it represents a new approach in the management of epilepsy, with a novel mechanism of action, and the potential to have a considerable impact on the treatment of adolescents with epilepsy. John Wiley and Sons Inc. 2016-06-28 /pmc/articles/PMC5036429/ /pubmed/27688936 http://dx.doi.org/10.1002/brb3.505 Text en © 2016 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Kim, Heung Dong Chi, Ching‐Shiang Desudchit, Tayard Nikanorova, Marina Visudtibhan, Anannit Nabangchang, Charcrin Chan, Derrick W. S. Fong, Choong Yi Chang, Kai‐Ping Kwan, Shang‐Yeong Reyes, Fe De Los Huang, Chao‐Ching Likasitwattanakul, Surachai Lee, Wang‐Tso Yung, Ada Dash, Amitabh Review of clinical studies of perampanel in adolescent patients |
title | Review of clinical studies of perampanel in adolescent patients |
title_full | Review of clinical studies of perampanel in adolescent patients |
title_fullStr | Review of clinical studies of perampanel in adolescent patients |
title_full_unstemmed | Review of clinical studies of perampanel in adolescent patients |
title_short | Review of clinical studies of perampanel in adolescent patients |
title_sort | review of clinical studies of perampanel in adolescent patients |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036429/ https://www.ncbi.nlm.nih.gov/pubmed/27688936 http://dx.doi.org/10.1002/brb3.505 |
work_keys_str_mv | AT kimheungdong reviewofclinicalstudiesofperampanelinadolescentpatients AT chichingshiang reviewofclinicalstudiesofperampanelinadolescentpatients AT desudchittayard reviewofclinicalstudiesofperampanelinadolescentpatients AT nikanorovamarina reviewofclinicalstudiesofperampanelinadolescentpatients AT visudtibhananannit reviewofclinicalstudiesofperampanelinadolescentpatients AT nabangchangcharcrin reviewofclinicalstudiesofperampanelinadolescentpatients AT chanderrickws reviewofclinicalstudiesofperampanelinadolescentpatients AT fongchoongyi reviewofclinicalstudiesofperampanelinadolescentpatients AT changkaiping reviewofclinicalstudiesofperampanelinadolescentpatients AT kwanshangyeong reviewofclinicalstudiesofperampanelinadolescentpatients AT reyesfedelos reviewofclinicalstudiesofperampanelinadolescentpatients AT huangchaoching reviewofclinicalstudiesofperampanelinadolescentpatients AT likasitwattanakulsurachai reviewofclinicalstudiesofperampanelinadolescentpatients AT leewangtso reviewofclinicalstudiesofperampanelinadolescentpatients AT yungada reviewofclinicalstudiesofperampanelinadolescentpatients AT dashamitabh reviewofclinicalstudiesofperampanelinadolescentpatients |